FLASCO

SlideThank You, Flasco Diamond Elite Corporate Members! Slide

Corporate Members

Diamond Elite

Astellas Pharma Bristol Meyers SquibbBristol Meyers Squibb Sanofi Genzyme

Diamond

BeiGene Genentech Guardant HealthGuardant Health TESARO, A GSK Company

Platinum

Daiichi SankyoDaiichi Sankyo Dova PharmaceuticalsDova Pharmaceuticals Janssen a Johnson and Johnson Company Karyopharm Therapeutics MorphoSys US Novartis OncologyNovartis Oncology SandozSandoz

Gold

Acrotech BiopharmaAcrotech Biopharma Agios PharmaceuticalsAgios Pharmaceuticals Blueprint Medicines Clovis Oncology Deciphera Epizyme EUSA PharmaEUSA Pharma Heron TherapeuticsHeron Therapeutics Rigel Pharmaceuticals ServierServier Verastem Oncology Walgreens

Latest News

Celgene

FDA approves Onureg (azacitidine tablets) for acute myeloid leukemia

From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the...

Celgene

FDA approves Onureg (azacitidine tablets) for acute myeloid leukemia

On September 1, 2020, the Food and Drug Administration approved azacitidine tablets (ONUREG®, Celgene Corporation) for continued treatment of patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. More information.

Bristol Myers Squibb

FDA approves Onureg (azacitidine tablets) for acute myeloid leukemia

From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the...

Janssen | Johnson & Johnson

FDA approves carfilzomib and daratumumab with dexamethasone for multiple myeloma

On August 20, 2020, the Food and Drug Administration approved carfilzomib (KYPROLIS, Onyx Pharmaceuticals, Inc.) and daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. The efficacy of carfilzomib and daratumumab with dexamethasone was evaluated in two...

FDA

CAR T-Cell Therapy Approved by FDA for Mantle Cell Lymphoma

A CAR T-cell therapy called brexucabtagene autoleucel (Tecartus) has been approved by the Food and Drug Administration (FDA) for some patients with mantle cell lymphoma. This is the third CAR-T cell therapy approved by FDA for patients with cancer. Read more >

Who’s Online

Profile picture of Katrina Williams